2004-11-16 |
2004-11-16 |
VP
Vente planifiée
|
DUNCAN MICHAEL R
VP and General Manager
Dirigeant
|
5 000
-87.5%
30,78
153 900 USD
|
5 000
-87.5%
|
30,78
|
153 900 USD
|
|
2004-11-12 |
2004-11-11 |
VP
Vente planifiée
|
GARRETT J STEVEN
Senior VP Clinical Research
Dirigeant
|
4 500
-55.1%
30,58
137 610 USD
|
4 500
-55.1%
|
30,58
|
137 610 USD
|
|
2004-11-08 |
2004-11-05 |
VP
Vente planifiée
|
BETHUNE DAVID R
CEO/Chairman
Administrateur exécutif
|
10 000
-6.4%
31,01
310 100 USD
|
10 000
-6.4%
|
31,01
|
310 100 USD
|
|
2004-10-19 |
2004-10-18 |
VP
Vente planifiée
|
DUNCAN MICHAEL R
VP and General Manager
|
800
-52.8%
30,14
24 108 USD
|
800
-52.8%
|
30,14
|
24 108 USD
|
|
2004-10-19 |
2004-10-18 |
VP
Vente planifiée
|
DUNCAN MICHAEL R
VP and General Manager
|
4 200
-85.5%
30,14
126 567 USD
|
4 200
-85.5%
|
30,14
|
126 567 USD
|
|
2004-10-12 |
2004-10-11 |
VP
Vente planifiée
|
GARRETT J STEVEN
Senior VP Clinical Research
|
1 200
-24.7%
30,39
36 468 USD
|
1 200
-24.7%
|
30,39
|
36 468 USD
|
|
2004-10-12 |
2004-10-11 |
VP
Vente planifiée
|
GARRETT J STEVEN
Senior VP Clinical Research
|
3 800
-43.8%
30,39
115 482 USD
|
3 800
-43.8%
|
30,39
|
115 482 USD
|
|
2004-10-06 |
2004-10-05 |
VP
Vente planifiée
|
BETHUNE DAVID R
CEO/Chairman
Administrateur exécutif
|
10 000
-6.4%
32,02
320 190 USD
|
10 000
-6.4%
|
32,02
|
320 190 USD
|
|
2004-09-16 |
2004-09-16 |
VP
Vente planifiée
|
DUNCAN MICHAEL R
VP and General Manager
Dirigeant
|
3 300
-85.7%
30,12
99 396 USD
|
3 300
-85.7%
|
30,12
|
99 396 USD
|
|
2004-09-16 |
2004-09-16 |
VP
Vente planifiée
|
DUNCAN MICHAEL R
VP and General Manager
Dirigeant
|
1 700
-75.6%
30,12
51 204 USD
|
1 700
-75.6%
|
30,12
|
51 204 USD
|
|
2004-09-14 |
2004-09-13 |
VP
Vente planifiée
|
GARRETT J STEVEN
Senior VP Clinical Research
Dirigeant
|
5 000
-58.8%
30,00
150 000 USD
|
5 000
-58.8%
|
30,00
|
150 000 USD
|
|
2004-09-08 |
2004-09-07 |
VP
Vente planifiée
|
BETHUNE DAVID R
CEO/Chairman
Administrateur exécutif
|
10 000
-6.4%
29,21
292 100 USD
|
10 000
-6.4%
|
29,21
|
292 100 USD
|
|
2004-08-16 |
2004-08-16 |
VP
Vente planifiée
|
DUNCAN MICHAEL R
VP and General Manager
Dirigeant
|
1 000
-64.5%
30,11
30 110 USD
|
1 000
-64.5%
|
30,11
|
30 110 USD
|
|
2004-08-16 |
2004-08-16 |
VP
Vente planifiée
|
DUNCAN MICHAEL R
VP and General Manager
Dirigeant
|
4 000
-87.9%
30,11
120 440 USD
|
4 000
-87.9%
|
30,11
|
120 440 USD
|
|
2004-08-11 |
2004-08-11 |
VP
Vente planifiée
|
GARRETT J STEVEN
Senior VP Clinical Research
Dirigeant
|
5 000
-58.8%
30,53
152 650 USD
|
5 000
-58.8%
|
30,53
|
152 650 USD
|
|
2004-08-05 |
2004-08-05 |
VP
Vente planifiée
|
BETHUNE DAVID R
CEO/Chairman
Administrateur exécutif
|
10 000
-6.4%
30,57
305 700 USD
|
10 000
-6.4%
|
30,57
|
305 700 USD
|
|
2004-07-19 |
2004-07-19 |
VP
Vente planifiée
|
WARREN STEPHEN L
VP R&D and CSO
|
5 000
-100.0%
33,50
167 500 USD
|
5 000
-100.0%
|
33,50
|
167 500 USD
|
|
2004-07-19 |
2004-07-16 |
V
Vente
|
DUNCAN MICHAEL R
VP and General Manager
|
7 000
-92.7%
33,50
234 500 USD
|
7 000
-92.7%
|
33,50
|
234 500 USD
|
|
2004-07-12 |
2004-07-12 |
VP
Vente planifiée
|
GARRETT J STEVEN
Senior VP Clinical Research
|
5 000
-41.3%
31,96
159 775 USD
|
5 000
-41.3%
|
31,96
|
159 775 USD
|
|
2004-07-06 |
2004-07-06 |
VP
Vente planifiée
|
BETHUNE DAVID R
CEO/Chairman
Administrateur exécutif
|
10 000
-6.4%
33,04
330 400 USD
|
10 000
-6.4%
|
33,04
|
330 400 USD
|
|